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Histone deacetylases (HDACs) play a major role in the regulation of chromatin structure and gene expression by 
changing acetylation status of histone and non-histone proteins. MS-275 (entinostat, MS) is a well-known ben-
zamide-based HDACI and Salermide (SAL), a reverse amide compound HDACI, have antiproliferative effects 
on several human cancer cells. In this study, we aimed to investigate the effects of HDACIs (MS and SAL) alone 
and/or combined use with EF24 (EF), a novel synthetic curcumin analog, on human pancreatic cancer cell line 
(BxPC-3). In vitro, BxPC-3 cells were exposed to varying concentrations of MS, SAL with or without EF, and 
their effects on cell viability, acetylated Histone H3 and H4 levels, cytotoxicity, and cleaved caspase 3 levels, 
and cell cycle distribution were measured. The viability of BxPC-3 cells decreased significantly after treatment 
with EF, MS and SAL treatments. MS and SAL treatment increased the acetylation of histone H3 and H4 in a 
dose dependent manner. MS and SAL alone or combined with EF were increased the number of cells in G1 
phase. In addition, treatment with agents significantly decreased the ratio of cell in G2/M phase. There were sig-
nificant dose-dependent increases at cleaved Caspase 3 levels after MS treatment but not after SAL treatment. 
Our results showed that HDAC inhibitors (MS and SAL), when combined with EF, may effectively reduce pan-
creatic cancer cell (BxPC-3) progression and stop the cell cycle at G1 phase. Further molecular analyses are 
needed to understand the fundamental molecular consequences of HDAC inhibition in pancreas cancer cells. 
 






Pancreas cancer is one of the most lethal 
malignancy seen in humans and fourth 
among death due to cancer in both sexes 
(Siegel et al., 2016). Molecular basis of pan-
creatic cancer development and progression 
includes both genetic and epigenetics altera-
tions (Lomberk and Urrutia, 2015). Gene ex-
pression is controlled by epigenetic mecha-
nisms such as DNA methylation, histone 
modifications and non-coding RNAs (Hol-
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och and Moazed, 2015) Histone modifica-
tions alter chromatin structure by affecting 
the functional interactions between the his-
tones or the connection of histones with 
DNA (Kouzarides, 2007). Acetylation of his-
tones is associated with a transcriptionally 
active chromatin structure among all known 
modification. The acetylation status of his-
tones is regulated by two enzyme families; 
histone acetyltransferases (HATs) and his-
tone deacetylases (HDACs) (Di Gennaro et 
al., 2004). The HDAC family consists of 
eighteen different human HDAC isoforms 
that are grouped into four classes; class I 
(HDAC1-3 and 8), class IIa (HDAC4, 5, 7 
and 9), class IIb (HDAC6 and 10), class III 
[sirtuins, (SIRT1-7)] and class IV 
(HDAC11) (Di Gennaro et al., 2004; Kou-
zarides, 2007). 
HDAC inhibitors (HDACIs) are classi-
fied according to their chemical structures 
and there are five classes of them including 
short-chain fatty acids, hydroxamic acids, 
cyclic tetrapeptides, aliphatic acids and ben-
zamides, MS-275 (MS), also called entino-
stat, is a benzamide type HDAC inhibitor 
(HDACi) and specific for class I HDACs 
(Khan and La Thangue, 2012). Its antiprolif-
erative effects has been shown in several 
cancer cell lines including cholangiocarci-
noma (Baradari et al., 2007), leukemia 
(Rosato et al., 2003; Gao et al., 2008), pedi-
atric solid tumors (Jaboin et al., 2002), glio-
blastoma (Eyüpoglu et al., 2006), prostate 
cancer (Khandelwal et al., 2008; Qian et al., 
2007), hepatoma (Gahr et al., 2008), bladder 
(Qu et al., 2010), and pancreas (Peulen et al., 
2013). 
Sirtuins belongs to the Class III HDACs. 
SIRT1 and SIRT2 have roles in several cel-
lular processes such as metabolic regulation, 
genomic stability, DNA repair, epigenetic si-
lencing and chromatin modification (Finkel 
and Deng, 2009). Their main substrates are 
histone proteins and dysregulation of SIRT1 
and SIRT2 expression is frequently found in 
several cancers (Roth and Chen, 2014). Sa-
lermide (SAL), an inhibitor of SIRT1 and 
SIRT2, is able to kill tumor cells (Lara et al., 
2009) including leukeamia, lymphoma, co-
lon, breast (Lara et al., 2009), lung (Liu et 
al., 2012), neuroblastoma and pancreatic 
cancer cells (Liu et al., 2013). After exposure 
of cancer cells to SAL, epigenetically si-
lenced proapoptotic genes are reactivated 
and thus, it generates antiproliferative effects 
on cancer cells (Lara et al., 2009). 
EF24 (EF), a synthetic curcumin analog 
(Adams et al., 2004), alone or combined with 
other agents shows anticancer effects on sev-
eral tumor cell lines including mesothelioma 
(Onen et al., 2015), ovarian (Tan et al., 
2010), colon (Subramaniam et al., 2008), 
prostate (Yang et al., 2013), and breast (Sun 
et al., 2009). With regard to the pancreatic 
cancer cells (MiaPaCa-2 and PANC-1), 
Lagisetty et al. (2012) showed the antiprolif-
erative effect of EF. Like curcumin, EF tar-
gets Nuclear Factor Kappa B (NF-κB) sig-
naling pathway and induce programmed cell 
death (Yang et al., 2013). 
The presence of HDACs (HDAC1-3) ex-
pression in human pancreatic cancer speci-
mens was shown by immunohistochemical 
analysis (Nakagawa et al., 2007). Moreover, 
aberrant expression of class 1 HDACs 
(HDAC1, HDAC3) and class 2 (HDAC7) 
was demonstrated in BxPC-3 cells (Ouaïssi 
et al., 2008, 2012). 
Lehmann et al. displayed notably associ-
ation between increased class I HDAC ex-
pression and elevated nuclear translocation 
of RelA/p65 (Lehmann et al., 2009). Moreo-
ver, Weichert et al. (2007) showed a signifi-
cant correlation between up-regulated 
RelA/p65 expression and induction of the 
NF-κB pathway in pancreatic cancer pa-
tients. It is also known that SIRT1 physically 
associates with the NF-κB complex (mainly 
RelA/p65 subunit), and suppress mRNA syn-
thesis via deacetylating RelA/p65 (Yeung et 
al., 2004). 
To our knowledge, the impact of EF 
alone or in combination with HDACIs (MS 
and SAL) on pancreatic cancer cell line 
(BxPC-3) has not been analyzed so far and 
thus we aimed to study possible effects of 
these agents by virtue of testing cell viabil-
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ity, histone acetylation, cell cycle analysis, 
caspase 3 activation and lactate dehydrogen-
ase release. 
 
MATERIALS AND METHODS 
Chemicals 
The reagents and kits used in this study 
were purchased from the following suppli-
ers: SAL (N-{3-[2-hydroxynaphthalen-1- 
ylmethylene)-amino]-phenyl}-2-phenylpro-
pionamidea, MS, EF, 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrasodium bromide 
(MTT), dimethyl sulfoxide (DMSO) and 
CelLytic from Sigma-Aldrich (St. Louis, 
MO, USA); Roswell Park Memorial Institute 
(RPMI)-1640 medium, fetal bovine serum 
(FBS), penicillin/streptomycin from Gibco 
(Grand Island, NY, USA); all of other chem-
icals and reagents from Sigma-Aldrich (St. 
Louis, MO, USA). 
 
Cell lines and culture conditions 
The human pancreatic cell line, BxPC-3 
(CRL-1687), was obtained from the Ameri-
can Type Culture Collection (ATCC, Manas-
sas, VA, USA) and grown in RPMI-1640 
medium supplemented with 10 % FBS and 
1 % penicillin/streptomycin, at 37 °C in a 
humidified atmosphere containing 5 % CO2. 
When BxPC-3 cells were 80 % confluent, 
they were sub-cultured to fresh medium. The 
cultures were incubated for 24 h before the 
experimental treatments.  
SAL, MS and EF were dissolved in 
100 % DMSO to make 1 mM stock solu-
tions, kept at -20 °C, and then diluted in the 
cell culture medium immediately prior to 
use. In all experiments, control cells were in-
cubated in media supplemented with DMSO 
alone. The final concentration of DMSO was 
maintained at 0.2 % and this concentration 




Cell viability was determined after alone 
and combinational treatment with SAL 
and/or MS at various concentrations with or 
without selected dose of EF (1 µM) by MTT 
assay. BxPC-3 cells were seeded at density 
of 5 × 103 cells/well in 96-well plates and in-
cubated overnight at 37 °C. This cell line 
was incubated with various concentrations of 
SAL (2.5 to 120 µM) and MS (2.5 to 75 µM) 
with selected dose of EF for 24 h. After in-
cubation with these agents, 10 μl of 5 mg/ml 
MTT in phosphate-buffered saline (PBS) 
was added to each well and the plates were 
incubated for an additional 4 h in the dark at 
37 °C. The supernatants were aspirated, and 
formazan crystals were solubilized in 100 μl 
DMSO at 37 °C for 10 min with agitation. 
The absorbance of each well was measured 
at 570 nm using Spectramax M3 microplate 
reader (Molecular Devices, Silicon Valley, 
California, USA). All experiments were per-
formed in quadruplicate for each dose. 
 
Acetylated Histone H3 and Acetyl-Histone 
H4 Sandwich ELISA assay 
Enzyme-linked immunosorbent assay 
(ELISA) was used to detect specifically en-
dogenous levels of acetylated lysines on his-
tones H3 and H4 in BxPC-3 cells in presence 
of MS and SAL at 24 h. PathScan® Acetylat-
ed Histone H3 and Acetyl-Histone H4 
Sandwich ELISA Kits from Cell Signaling 
Technology were used according to the 
manufacturers’ instructions. Absorbance of 
each well was measured using Spectramax 
M3 microplate reader (Molecular Devices) at 
450 nm. The absorbance of each sample was 
divided by the absorbance of the untreated 
cell with the same incubation time to calcu-
late a control index. All experiments were 
carried out in triplicate. 
 
Flow cytometric analysis of the cell cycle 
BxPC-3 cells (1 × 106) were treated with 
SAL and/or MS at various concentrations 
with or without 1 µM EF for 24 h. After 
trypsinization, detached cells were washed 
with PBS and then processed with a Cy-
cleTest-PlusTM DNA reagent KIT (Becton 
Dickinson and Company BD Biosciences, 
San Jose, CA, USA). DNA QC particles 
(Becton Dickinson) were used as controls. 
The samples were analyzed using FACScan 
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(Becton Dickinson) and the data were col-
lected by Cell Quest (Becton Dickinson) and 
analyzed by use of FCS Express 5 Flow Re-
search Edition software. These experiments 
were carried out in triplicate and inde-
pendently repeated at least three times. 
 
Cytotoxicity assay 
The lactate dehydrogenase (LDH) Cyto-
toxicity Detection Kit Plus (Roche Applied 
Science, Mannheim, Germany) was used to 
measure the cytotoxicity in MS, SAL and/or 
EF-treated BxPC-3 cells. Briefly, cells were 
treated with selected concentrations of MS 
and SAL with or without 1 µM EF for 24 h. 
After treatment of BxPC-3 cells with agents 
at various concentrations, this assay was per-
formed according to the manufacturer’s in-
structions. Optical density (OD) was meas-
ured following incubation at 490 nm using 
Spectramax M3 microplate reader (Molecu-
lar Devices, USA).  
 
Detection of cleaved caspase 3 level 
The presence of cleaved caspase-3 pro-
tein levels in BxPC-3 cells, which are im-
portant signs of apoptosis, was detected us-
ing the PathScan® Cleaved Caspase-3 
(Asp175) Sandwich Elisa Kit (Cell Signaling 
Technology Inc., Beverly, MA, USA). Brief-
ly, after being treated with agents at indicat-
ed concentrations for 24 h, cell lysates were 
obtained and then protein content of the cell 
lysates was determined using the bicincho-
ninic acid (BCA)™ protein assay kit (Pierce, 
Rockford, Illinois, USA). This assay was 
performed according to the the manufactur-
er’s protocols. At the end of this period, the 
absorbance of the cleaved Caspase-3 levels 
was measured at 450 nm with Spectramax 




All the quantitative data were presented 
as the mean values ± standard deviations 
(SD). Statistical comparisons among groups 
were performed by Student's t-test or one-
way analysis of variance (ANOVA) fol-
lowed by the Tukey test for multiple com-
parison. The values of p < 0.05 were consid-




Effects of MS, SAL and EF on the BxPC-3 
cell viability 
The BxPC-3 cells were treated with in-
creasing concentrations of EF, MS and SAL 
and the effects on cell viability were assessed 
by enzymatic reduction of MTT. BxPC-3 
cell lines were administered EF (0.5-60 μM), 
MS (2.5-25 μM), and SAL (5-100 μM), and 
dose-dependent effects of these agents on the 
cells were defined after 24 h.  
As shown in Figure 1a, the viability of 
BxPC-3 cells decreased significantly after 
treatment with EF. Moreover MS and SAL 
alone or with EF treatment was also shown 
to decrease the cell viability in a concentra-
tion-dependent manner (Figure 1b and 1c, 
respectively). The half-maximal inhibitory 
concentration (IC50) values of MS was about 
25 µM and SAL was 40 µM for 24 h. IC50 
value for EF was found to be 60 µM.  
Then cells were treated with 1 µM EF 
plus different doses of MS or SAL and cell 
viability was assessed after 24 h by MTT. 
Combined treatment of 1 µM EF with MS 
enhanced the antiproliferative effect of MS 
at all concentrations and it was clearly re-
duced the IC50 concentration of MS up to 
10 µM (Figure 1b). 
However, combined treatment of 1 µM 
EF with SAL attenuated the inhibitory effect 
of SAL alone treatment and increased the 
IC50 concentration of SAL about 80 µM 
(Figure 1c). 
 
Determination of Acetylated Histone H3 
and Histone H4 Levels 
Treatment of BxPC-3 cells with different 
concentration of MS (2.5–75 µM) (Figure 
2a) and SAL (5–100 µM) (Figure 2b) alone 
was found to increase both acetylated histone 
H3 and H4 levels. MS increased the acetyla-
tion of histone H3 and H4 in a dose depend-
ent manner. At the highest MS concentration  
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Figure 1: Effect of MS and SAL alone or in com-
bination with EF on the viability of pancreatic 
cancer cells. Statistical significance was deter-
mined using two-way analysis of variance, a: EF 
alone, b: MS alone and MS+EF treatment, c: 
SAL alone and SAL+EF treatment. MS: MS-275; 
SAL: Salermide; EF: EF24.  
* p < 0.001, versus control cells for 24 h 
† p < 0.001, versus EF treatment for 24 h 
 
 
(75 µM), 3.5 fold increased acetyl histone 
H3 and H4 was found after 24 h. 
For the SAL treatment, dose dependent 
increase in the acetylation status of histones 
was not found like in MS treatment. Most of 
the SAL doses mainly elevated the histone 
H3 and H4 acetylation up to 2 fold (Figure 
2b). 
 
Cytotoxic effect of MS and/or SAL alone 
and combination treatment with EF 
The effects of three concentrations of MS 
(5, 10 and 20 µM) and SAL (10, 40 and 
80 µM), as single agents and combined 
treatment with 1 µM EF, were evaluated on 
BxPC-3 cells for 24 h using LDH release to 
culture medium (Figure 3). For all concen-
trations of the agents cytotoxicity ratio were 
not exceed 3.5 %. 
 
Cell cycle perturbation by HDACI and their 
combinations with EF 
MS, SAL and EF significantly affected to 
BxPC3 cell cycle progression as compared to 
the control cells at 24 h (Figure 4). In flow 
cytometry analysis, the percentage of control 
BxPC-3 cells in each phase was stable. In 
addition, MS and SAL produced a consistent 
 
 
Figure 2: Acetylated histone H3 and H4 levels in 
BxPC-3 cells treated with MS (a) and SAL (b) 
alone or in combination with EF for 24 h. MS: 
MS-275; SAL: Salermide; EF: EF24 *p < 0.001.  
 
 
Figure 3: Cytotoxicity of MS and SAL alone or in 
combination with EF evaluated by LDH release 
from BxPC-3 cells after 24 h of incubation. LDH: 
lactate dehydrogenase; MS: MS-275; SAL: Sa-
lermide; EF: EF24 
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increase of cells in the G1 phase of cell cycle 
in BxPC-3 cell lines. Moreover, combined 
treatments of MS and SAL with EF were al-
so increased the number of cells in G1 phase. 
As seen in Figure 4, treatment with agents 
also significantly decreased the ratio of cell 
in G2/M phase. 
 
 
Figure 4: Effect of MS (a) and SAL (b) alone or 
in combination with EF on cell cycle by PI incor-
poration. Percentage of cells in each phase of 
the cell cycle (G1, S, and G2-M) is indicated. 
MS: MS-275; SAL: Salermide; EF: EF24.  
* p < 0.001, versus control cells for 24 h 
† p < 0.001, versus EF treatment for 24 h 
 
 
Apoptosis induction by HDACI and their 
combinations with EF 
To investigate further whether the induc-
tion of apoptosis by MS and SAL is mediat-
ed by classical apoptotic pathways, we ana-
lyzed the levels of cleaved caspase 3, a well-
known mediator of apoptotic pathways. 
There were significant dose-dependent in-
creases (ranges from 2-fold to 3-fold) at 
cleaved Caspase 3 levels after MS for 24 h 
(p < 0.05) (Figure 5). When correspond to 
control cells, MS + EF administration in-
creased the level of cleaved caspase 3 in 
BxPC-3 cells (p < 0.05, Figure 5).  
Cleaved caspase-3 protein levels de-
creased dose dependent manner with SAL in 
BxPC-3 cells (Figure 5). Moreover, the 
combination of SAL and EF caused decrease 
in cleaved caspase-3 levels in these cells af-
ter 24h, as compared to control cells 
(p > 0.05) (Figure 5).  
 
 
Figure 5: Effects of MS and SAL alone or in 
combination with EF on levels of caspase-3 
cleavage in BxPC-3 cells, as measured by color-
imetric assay at 24 h. *p < 0.001, compared with 
control cells for 24 h. MS: MS-275; SAL: Saler-




Expression profiles of the HDAC and 
SIRT enzyme types in pancreatic cancer 
cells and impact of HDACIs on their expres-
sion were analyzed in some studies. With 
this regard, mRNA expression level of 
HDAC (1-7) and class III (SIRT1-6) was 
shown in pancreatic cell lines (MiaPaCa-2, 
BxPC-3, PANC-1, SOJ-6). Compared with 
the mRNA expression level of HDAC (1-7), 
it was observed that diminished SIRT (1-6) 
mRNA expression level in BxPC-3 cells 
(Ouaïssi et al., 2008). However, there was no 
difference between protein expression level 
of HDAC (1, 4, 7) and SIRT (1, 2) in BxPC-
3 cells (Ouaïssi et al., 2008). Moreover, 
Quaissi et al. (2012) analyzed the effects of 
HDACi [TSA and panobinostat (LBH589)] 
on the mRNA expression of HDAC genes 
(HDAC 1-4, 7 and SIRT 1, 2) from the pan-
creatic cell lines (BxPC-3, PANC-1 and 
SOJ-6) and non-malignant pancreatic epithe-
lial cell line (HPDE/E6E7). Both TSA and 
panobinostat has no impact on mRNA ex-
pression of HDAC genes in BxPC-3 cells. 
However, protein expression of four studied 
genes was either increased or decreased by 
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LBH589 and TSA administration on BxPC-3 
cells (Ouaïssi et al., 2012). Due to the fact 
that apoptosis level was higher in TSA-
treated BxPC-3 cells than those of cells 
treated with 5-aza-dC, histone deacetylation 
is suggested to take a part in the progression 
in BxPC-3 (Cai et al., 2011). 
After inhibition of class I HDACs, it is 
suggested that genes controlled by NF-κB 
pathway can be activated to allow cancer cell 
proliferation. From this point, Peulen et al. 
(2013) displayed that suppression of HDAC1 
and HDAC3 promoted upregulation of 
COX-2 expression through activation of NF-
κB pathway in BxPC-3 cells. So, inhibition 
of the NF-κB pathway using 1 µM EF de-
creased the cancer cells proliferation less 
than 60 % in pancreatic cancer cells (Mi-
aPaCa-2 and PANC-1) (Lagisetty et al., 
2012). Similarly, our EF treatment of another 
pancreas cancer cell line (BxPC-3) also re-
duced the cell viability by 80 % (Figure 1a). 
Because of the relationship between class I 
HDACs and NF-κB pathway, we want to an-
alyze the effect of dual inhibition of class I 
HDAC by MS and NF-κB pathway via EF 
on BxPC-3 cells. To our knowledge, such a 
dual inhibition targeting both class I HDACs 
and NF-κB pathway has not been investigat-
ed so far.  
In vitro analysis performed on pancreatic 
cancer cell lines showed different effects of 
HDACIs alone (Peulen et al., 2013; Sato et 
al., 2004) or in combination with classical 
chemotherapeutics (Qiao et al., 2013) and 
these differences can be attributed to the 
characteristics of the cell line and/or the 
chemical properties of HDACi. HDACIs af-
fect cell proliferation, cell cycle progression 
(Ouaïssi et al., 2008; Qiao et al., 2013; Chun 
et al., 2009; Zhang et al., 2008), gene ex-
pression (Chun et al., 2009; Emonds et al., 
2010; Sato et al., 2004) and also miRNA ex-
pression (Zhang et al., 2008) in pancreas 
cancer cells. 
Most of the analyzed HDACIs exert an-
tiproliferative and apoptotic effects on pan-
creas cancer cells. Sato et al. (Sato et al., 
2004) displayed antiproliferative effect of 
HDACi (FR901228) in five human pancreat-
ic cell lines (MiaPaCa-2, Capan-1, BxPC-3, 
HPAF and Panc-1). In addition, treatment of 
BxPC-3 cells with TSA caused stimulation 
of apoptosis by mitochondria-dependent 
pathway (Ouaïssi et al., 2008). Moreover, it 
was shown that TSA treatment diminished 
the cell viability of BxPC-3 at various con-
centration (range 0.1-0.2 µmol/L) for 24 – 
72 h. Compared with the control cells, ele-
vated levels of apoptosis was also deter-
mined in TSA-treated BxPC-3 cells (Zhang 
et al., 2008). Ouaïssi et al. (2012) showed 
that following incubation with the TSA or 
LBH589, apoptosis induced in BxPC-3 cells 
in dose-and time-dependent manner, as well. 
Furthermore, LBH589 was shown to induce 
tumor regression in BxPC-3 xenografts 
(Ouaïssi et al., 2008). Peulen et al. (2013) 
showed that cell growth was inhibited in re-
sponse to MS treatment on different human 
pancreas cancer cells (BxPC-3, CFPAC-1 
and PANC-1) in a dose and time dependent 
manner. At 48 h, 1 μM concentration of MS 
diminished BxPC-3 cell viability by 50 % 
and 5 μM concentration of MS suppressed 
totally cell viability. Similar to above data, 
we found antiproliferative effects of MS on 
BxPC-3 cell line in a dose dependent manner 
(Figure 1b)  
With respect to the apoptotic effects of 
HDACIs, several studies showed molecular 
basis of programmed cell death seen after 
HDACi treatment. Following treatment of 
human pancretatic cancer cells (BxPC-3, 
CAPAN-1 and AsPC-1) with TSA resulted 
in upregulation of acetyl H3, p21Waf1 and 
Bax levels, increased phosphorylation of p38 
and diminished phosphorylation of ERK 1/2 
and AKT (Zhang et al., 2008). In PANC-1 
and BxPC-3 cells, it was also shown that 
apoptosis was correlated with the enhanced 
nuclear localization of survivin, up-regulated 
expression of BAX, and stimulation of 
caspase 3/7 (Chun et al., 2009). Moreover, In 
five human pancreas cell lines (MiaPaCa-2, 
Capan-1, BxPC-3, HPAF and PANC-1), 
FR901228 triggered apoptosis through in-
duction of caspase-3, degradation of survivin 
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and p21Waf-1 (Sato et al., 2004). From these 
results, it is obvious that induction of caspase 
3 is one of the common consequence seen af-
ter HDAC inhibitor exposure. Similarly, we 
found that MS treatment of BxPC-3 cells el-
evated histone H3 and H4 acetylation and 
cleaved caspase 3 levels (Figure 2a and 5, re-
spectively). But, Peulen et al. (2013) was un-
able to show apoptosis in BxPC-3 cells after 
24, 48 or 72 h of treatment with MS at doses 
ranges between 0.1-5 µM.  
HDACIs are capable of arresting cell cy-
cle progression at different phases depending 
on the inhibitor and cell type. For example, 
Chun et al. (2009) displayed that overexpres-
sion mRNA levels of p21CDKN1A and 
p27CDKN1B and diminished mRNA expres-
sion of cyclin D1 (CCND1) resulted in 
G0/G1 cell cycle arrest. In addition, after ad-
ministration of TSA in BxPC-3 cells, de-
creased cell proliferation and G1 arrest were 
detected (Ouaïssi et al., 2008; Zhang et al., 
2008). Moreover, it was shown that 50 % of 
the cells were arrested at the G1 phase by 
adding MS for 48 h (Peulen et al., 2013). In 
concert with these findings, we also showed 
an increase in the number of G1 subpopula-
tion of cells after MS treatment of BxPC-3 
cells (Figure 4a). On the other hand, Sato et 
al. (2004) displayed G2/M arrest in BxPC-3 
cells after 24 h incubation of FR901228. 
Chidamide (CS0055/HBI-8000), a newly 
discovered HDACi, belongs to benzamide 
class was treated on pancreatic cancer cells 
(BxPC-1 and PANC-1) (Qiao et al., 2013). 
After administration of this inhibitor on these 
cell lines, it was shown that cells arrested at 
G2/M phase of the cell cycle due to activa-
tion of p21 (Qiao et al., 2013). 
While promising anticancer effects 
against pancreas cancer cell lines were 
shown for HDACIs, little is known how they 
affect patients. In a Phase I study, combina-
tion of entinostat, MS, with 13-cis retinoic 
acid (CRA) in patient with unresectable pan-
creatic cancer resulted stable disease up to 
six months. But, an objective response was 
not reported after this regimen (Pili et al., 
2012). Further phase studies are needed to 
clarify the beneficial impacts of HDACIs 
alone or combined regimens on cancer pa-
tients. 
Lara et al. (2009) analyzed the effects of 
SAL on normal fibroblast cells and several 
cancer cell lines including leukeamia, lym-
phoma, colon and breast. They showed a cell 
number reduction in all studied cancer cells, 
but not normal fibroblast cells. In these cells, 
SAL was also found to induce apoptosis with 
varying degrees in a cell-type and dose de-
pendent manner. In another study, SAL was 
found to cause apoptotic cell death via endo-
plasmic reticulum stress induction in a dose 
and time dependent manner in human lung 
cancer cell lines (Liu et al., 2012). In neuro-
blastoma (BE(2)-C) and pancreatic cancer 
cells (MiaPaca-2), the SIRT2 inhibitor SAL 
was shown to diminish the N-Myc and c-
Myc protein levels, but not mRNA expres-
sion (Liu et al., 2013). SAL reduced the pan-
creatic cancer cell (MiaPaca-2) number by 
80 % at 25 µM concentration after 72h 
treatment (Liu et al., 2013). Our results also 
showed that SAL reduced cell viability and 
caused cell cycle arrest at G1 phase in 
BxPC-3 cells, but not increased the cleaved 
caspases 3 levels (Figure 1c, 4b, and 5, re-
spectively). 
Briefly, our results showed that HDACIs 
(MS and SAL), when combined with EF, 
may effectively reduce pancreatic cancer cell 
(BxPC-3) progression and stop the cell cycle 
at G1 phase. Further studies are needed to 
clarify the underlying molecular mechanisms 
of HDAC inhibition in pancreas cancer cells. 
This may be resulted in a development of 
more effective agents and promising therapy 
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